Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,301 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of MIL62, a novel glycoengineered type Ⅱ anti-CD20 monoclonal antibody, combined with lenalidomide in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma: a multicentre, single-arm, phase 1b/2 trial.
Shi Y, Zhou K, Zhou H, Qin Y, Jing H, Xiang Y, Wang Z, Wang Z, Zang A, Bai O, Li Z, Zhang H, Song Y, Liang J, Wei M. Shi Y, et al. Among authors: jing h. EClinicalMedicine. 2024 Jun 20;73:102702. doi: 10.1016/j.eclinm.2024.102702. eCollection 2024 Jul. EClinicalMedicine. 2024. PMID: 39007066 Free PMC article.
5-Hydroxymethylcytosine profiles of cfDNA are highly predictive of R-CHOP treatment response in diffuse large B cell lymphoma patients.
Chen HY, Zhang WL, Zhang L, Yang P, Li F, Yang ZR, Wang J, Pang M, Hong Y, Yan C, Li W, Liu J, Xu N, Chen L, Xiao XB, Qin Y, He XH, Liu H, Zhu HC, He C, Lin J, Jing HM. Chen HY, et al. Among authors: jing hm. Clin Epigenetics. 2021 Feb 11;13(1):33. doi: 10.1186/s13148-020-00973-8. Clin Epigenetics. 2021. PMID: 33573703 Free PMC article.
The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study.
Zhang W, Su L, Liu L, Gao Y, Wang Q, Su H, Song Y, Zhang H, Shen J, Jing H, Wang S, Cen X, Liu H, Liu A, Li Z, Luo J, He J, Wang J, O'Connor OA, Zhou D. Zhang W, et al. Among authors: jing h. Cancer Biol Med. 2021 Mar 23;18(3):841-8. doi: 10.20892/j.issn.2095-3941.2020.0413. Online ahead of print. Cancer Biol Med. 2021. PMID: 33755379 Free PMC article.
Treatment and outcome patterns of patients with Waldenström's macroglobulinemia: a large, multicenter retrospective review in China.
Cao XX, Yi SH, Jiang ZX, He JS, Yang W, Du J, Sun CY, Wu Y, Chen WM, Liu XJ, Li BZ, Li CR, Sang W, Liu QH, Chu XX, Li F, Bai O, Mao M, Fu R, Wang W, Liu LH, Wang LQ, Dong YJ, Luo J, Li ZL, Wei YQ, Zhang QK, Liu J, Ding KY, Zou L, Chen BY, Hua LM, Jing HM, He J, Wang L, Li J, Qiu LG. Cao XX, et al. Leuk Lymphoma. 2021 Nov;62(11):2657-2664. doi: 10.1080/10428194.2021.1938030. Epub 2021 Jun 9. Leuk Lymphoma. 2021. PMID: 34105439
Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study.
Zhang Y, Liu P, Cai J, Jing H, Zou L, Huang H, Wu Y, Li W, Zhong L, Jin X, Ye X, Feng R, Zhang H, Zhang L, Lin L, Sun X, Tian Y, Xia Z, Li Z, Huang H, Xia Y, Cai Q. Zhang Y, et al. Among authors: jing h. Cancer Med. 2022 Nov;11(22):4134-4145. doi: 10.1002/cam4.4765. Epub 2022 Apr 19. Cancer Med. 2022. PMID: 35438258 Free PMC article.
2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
Li P, Liu Y, Liang Y, Bo J, Gao S, Hu Y, Hu Y, Huang H, Huang X, Jing H, Ke X, Li J, Li Y, Liu Q, Lu P, Mei H, Niu T, Song Y, Song Y, Su L, Tu S, Wang J, Wu D, Wang Z, Xu K, Ying Z, Yang Q, Zhang Y, Shi F, Zhang B, Zhang H, Zhang X, Zhao M, Zhao W, Zhao X, Huang L, Zhu J, Qian W, Han W, Liang A. Li P, et al. Among authors: jing h. Cancer Biol Med. 2023 Mar 2;20(2):129-46. doi: 10.20892/j.issn.2095-3941.2022.0585. Cancer Biol Med. 2023. PMID: 36861439 Free PMC article.
Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study.
Deng LJ, Zhou KS, Liu LH, Zhang MZ, Li ZM, Ji CY, Xu W, Liu T, Xu B, Wang X, Gao SJ, Zhang HL, Hu Y, Li Y, Cheng Y, Yang HY, Cao JN, Zhu ZM, Hu JD, Zhang W, Jing HM, Ding KY, Zhang XY, Zhao RB, Zhang B, Tian YM, Song YP, Song YQ, Zhu J. Deng LJ, et al. Blood Adv. 2023 Aug 22;7(16):4349-4357. doi: 10.1182/bloodadvances.2022009168. Blood Adv. 2023. PMID: 37078706 Free PMC article. Clinical Trial.
Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.
Xia Z, Leng Y, Fang B, Liang Y, Li W, Fu C, Yang L, Ke X, Jiang H, Weng J, Liu L, Zhao Y, Zhang X, Huang Z, Liu A, Shi Q, Gao Y, Chen X, Pan L, Cai Z, Wang Z, Wang Y, Fan Y, Hou M, Ma Y, Hu J, Liu J, Zhou J, Zhang X, Meng H, Lu X, Li F, Ren H, Huang B, Shao Z, Zhou H, Hu Y, Yang S, Zheng X, Wei P, Pang H, Yu W, Liu Y, Gao S, Yan L, Ma Y, Jing H, Du J, Ling W, Zhang J, Sui W, Wang F, Li X, Chen W. Xia Z, et al. Among authors: jing h. BMC Cancer. 2023 Oct 14;23(1):980. doi: 10.1186/s12885-023-11489-8. BMC Cancer. 2023. PMID: 37838670 Free PMC article. Clinical Trial.
2,301 results